1. Home
  2. LSAK vs AGEN Comparison

LSAK vs AGEN Comparison

Compare LSAK & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSAK
  • AGEN
  • Stock Information
  • Founded
  • LSAK 1997
  • AGEN 1994
  • Country
  • LSAK South Africa
  • AGEN United States
  • Employees
  • LSAK N/A
  • AGEN N/A
  • Industry
  • LSAK Investment Bankers/Brokers/Service
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LSAK Finance
  • AGEN Health Care
  • Exchange
  • LSAK Nasdaq
  • AGEN Nasdaq
  • Market Cap
  • LSAK N/A
  • AGEN 286.0M
  • IPO Year
  • LSAK N/A
  • AGEN 2000
  • Fundamental
  • Price
  • LSAK $4.89
  • AGEN $7.71
  • Analyst Decision
  • LSAK
  • AGEN Strong Buy
  • Analyst Count
  • LSAK 0
  • AGEN 2
  • Target Price
  • LSAK N/A
  • AGEN $70.00
  • AVG Volume (30 Days)
  • LSAK 45.4K
  • AGEN 568.5K
  • Earning Date
  • LSAK 09-10-2024
  • AGEN 08-06-2024
  • Dividend Yield
  • LSAK N/A
  • AGEN N/A
  • EPS Growth
  • LSAK N/A
  • AGEN N/A
  • EPS
  • LSAK N/A
  • AGEN N/A
  • Revenue
  • LSAK $551,325,000.00
  • AGEN $161,416,000.00
  • Revenue This Year
  • LSAK $9.63
  • AGEN $43.78
  • Revenue Next Year
  • LSAK $8.35
  • AGEN N/A
  • P/E Ratio
  • LSAK N/A
  • AGEN N/A
  • Revenue Growth
  • LSAK 6.72
  • AGEN 69.94
  • 52 Week Low
  • LSAK $3.00
  • AGEN $4.78
  • 52 Week High
  • LSAK $5.33
  • AGEN $34.80
  • Technical
  • Relative Strength Index (RSI)
  • LSAK 58.25
  • AGEN 28.20
  • Support Level
  • LSAK $4.76
  • AGEN $14.77
  • Resistance Level
  • LSAK $4.96
  • AGEN $18.74
  • Average True Range (ATR)
  • LSAK 0.12
  • AGEN 1.46
  • MACD
  • LSAK 0.01
  • AGEN -0.45
  • Stochastic Oscillator
  • LSAK 79.41
  • AGEN 8.62

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: